Lenvatinib Suppresses Angiogenesis through the Inhibition of both the VEGFR and FGFR Signaling Pathways

• Main Authors: Kenji Ichikawa (Author), Saori Watanabe Miyano (Author), Yusuke Adachi (Author), Masahiro Matsuki (Author), Kiyoshi Okamoto (Author), Junji Matsui (Author)
• Formato: Libro
• Publicado: Global Journal of Cancer Therapy - Peertechz Publications, 2016-07-02.
• Subjects: Research Article
• Acceso en liña: Connect to this object online.

<p>Lenvatinib mesilate (lenvatinib) is an oral multiple-receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of Vascular Endothelial Growth Factor Receptor (VEGFR) 1-3, Fibroblast Growth Factor Receptor (FGFR) 1-4, Platelet-Derived Growth Factor Receptor (PDGFR) α...